Aster DM Q3 FY26: revenue up 13% YoY, PAT dips; board approves ESOP 2026
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 2.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q3 FY26 results. Consolidated revenue at INR 1,185.76 Cr (up 12.9% YoY); 9M at INR 3,460.84 Cr (up 10.3%). Q3 PAT dipped to INR 58.65 Cr vs INR 64.39 Cr due to exceptional items of INR 28.29 Cr (labour code provisions, merger costs). Board also approved ESOP Scheme 2026, conversion of INR 129.35 Cr loan into equity of subsidiary Aster DM Multispecialty Hospital, and powers to give loans/guarantees to group companies. Auditor Deloitte Haskins and Sells gave unmodified opinion.
Steady revenue growth but Q3 PAT hit by one-time labour code costs. ESOP and loan-to-equity moves are routine. Watch merger with Quality Care India.